111 related articles for article (PubMed ID: 22673388)
1. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0.
Ventura-Ríos L; Bañuelos-Ramírez D; Hernández-Quiroz Mdel C; Robles-San Román M; Irazoque-Palazuelos F; Goycochea-Robles MV
Reumatol Clin; 2012; 8(4):189-94. PubMed ID: 22673388
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
3. Infections in patients with rheumatoid arthritis treated with biologic agents.
Listing J; Strangfeld A; Kary S; Rau R; von Hinueber U; Stoyanova-Scholz M; Gromnica-Ihle E; Antoni C; Herzer P; Kekow J; Schneider M; Zink A
Arthritis Rheum; 2005 Nov; 52(11):3403-12. PubMed ID: 16255017
[TBL] [Abstract][Full Text] [Related]
4. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
[TBL] [Abstract][Full Text] [Related]
6. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
[TBL] [Abstract][Full Text] [Related]
8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
Marchesoni A; Zaccara E; Gorla R; Bazzani C; Sarzi-Puttini P; Atzeni F; Caporali R; Bobbio-Pallavicini F; Favalli EG
Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
[TBL] [Abstract][Full Text] [Related]
10. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
Régnier-Rosencher E; Farhi D; Lebrun A; Salliot C; Dougados M; Dupin N
Dermatology; 2012; 224(1):72-83. PubMed ID: 22487697
[TBL] [Abstract][Full Text] [Related]
13. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
14. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
16. [Cancer in arthritis patients after anti-tumour necrosis factor therapy].
Dreyer L; Mellemkjaer L; Hetland ML
Ugeskr Laeger; 2009 Feb; 171(7):506-11. PubMed ID: 19210932
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
[TBL] [Abstract][Full Text] [Related]
18. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
19. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
20. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
